11 assets in Testicular Cancer

Therapeutic assets addressing Testicular Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pedmark® Sts Testicular Cancer	University of Arizona	P1/2	CC (45)
Tarlatamab Testicular Cancer	University of Arizona	P1/2	CC (45)
Carboplatin Testicular Cancer	National Cancer Institute (NCI)	P1	CC (43)
Fapi-46 Testicular Cancer	Jonsson Comprehensive Cancer Center	P1	CC (43)
Fludeoxyglucose Testicular Cancer	Jonsson Comprehensive Cancer Center	P1	CC (43)
Veliparib Testicular Cancer	National Cancer Institute (NCI)	P1	CC (43)
asp1893 Testicular Cancer	Astellas Pharma Global Development, Inc.	P1	CC (41)
Brodalumab Testicular Cancer	Brian Henick, MD	P1	CC (41)
Ctim-76 Testicular Cancer	Context Therapeutics Inc.	P1	CC (41)